News

 
Following are announcements of notable deals and cases on which Davis Polk has advised, as well as a range of other news items about the firm and our lawyers. 
April 12, 2021 Diagnósticos da América R$3.3 billion equity offering
We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering
April 12, 2021 Ionis Pharmaceuticals $632.5 million convertible senior notes offering
We advised the purchasers on the Rule 144A convertible notes offering
April 12, 2021 Maravai LifeSciences $646.9 million secondary offering
We advised the joint book-running managers on the equity offering
April 1, 2021 Beam Therapeutics $300 million at-the-market offering
We advised the sales agent in connection with the equity offering
March 30, 2021 LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
March 30, 2021 Alignment Healthcare $489.6 million IPO
We advised the underwriters on the IPO and Nasdaq listing
March 26, 2021 Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock
March 24, 2021 Solid Biosciences $143.75 million follow-on equity offering
We advised the joint book-running managers on the stock offering
March 24, 2021 Charles River Laboratories International $1 billion senior notes offering
We advised Charles River Laboratories on the high-yield debt offering
March 23, 2021 Connect Biopharma $219.9 million IPO
We advised the underwriters on the IPO and Nasdaq listing

News

News Search: